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Background and objectives: Cardiovascular implantable electronic devices (CIED) are frequently
implanted in patients on anti-thrombotic agents. Pocket hematomas are more likely to occur in these
patients. The use of a sterile surgical drain in the pulse generator pocket site could prevent hematomas,
but fear of infection precludes its use. The objective of the present study is to study the safety and efﬁcacy
of surgical drain in patients on antithrombotics undergoing CIED implantations.
Methods: This is a single-centre, retrospective study involving patients undergoing CIED implantations on
antithrombotics (antiplatelets and anticoagulants) from August 2013 to July 2016. Patients with high risk
of thromboembolism were continued on oral antithrombotics or were bridged with heparin after
stopping oral antithrombotics. A sterile close wound suction drain was placed in device pockets following
CIED implantations. Post procedure, pressure dressing was applied and removed after 12 h once the drain
volume was less than 10 ml in 24 h.
Results: Sixty seven patients required surgical drain implantation. Major indications for antithrombotic
use were presence of intracoronary stent, atrial ﬁbrillation and mechanical valve replacements. The mean
post-procedural hospital stay was 3  0.9 days and mean overall drain was 16.6  8.2 ml. At a mean
follow up of 17.6  8.2 months, one patient (1.4%) had pocket hematoma. There were no infections.
Conclusion: The use of a surgical drain in CIED implantation signiﬁcantly reduces the risk of hematoma
formation without increasing the risk of infection. Antithrombotic drugs can be safely continued at the
time of implantation of cardiac devices.
© 2017 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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An increasing number of patients are undergoing cardiovascu-
lar implantable electronic device (CIED) procedures for various
indications.1–3 A signiﬁcant proportion of them are on antith-
rombotic therapy (anticoagulant, antiplatelet agents or both).4–6
Pocket hematoma is a well recognized complication associated
with CIED procedures and its risk is signiﬁcantly higher when
patients are on antithrombotic therapy.7–10 It also increases the
risk of infection in patients undergoing CIED implantations.11–13
Avoiding perioperative anticoagulation therapy on the other hand
increases the risk of thromboembolic events, in particular, cerebral
stroke.6,14,15 Interruption of anticoagulation therapy and bridging* Corresponding author at: Arrhythmia and Electrophysiology Services, Depart-
ment of Cardiology CARE Hospital, Road No1, Banjara Hills, Hyderabad, 500 034,
India.
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0019-4832/© 2017 Published by Elsevier B.V. on behalf of Cardiological Society of India. Th
org/licenses/by-nc-nd/4.0/).with heparin has also not been found to be safe.16,17 Surgical drains
during CIED implantation can prevent pocket hematoma and
infection in patients who require continued use of antithrombotic
therapy.
We evaluated the use of closed wound suction drainage system
(surgical drain) in patients undergoing CIED implantations to
prevent bleeding complications while on antithrombotic treat-
ment. The aim was to evaluate the safety and efﬁcacy of surgical
drain in preventing pocket hematoma in patients who are at high
risk for bleeding during CIED implantations.
2. Methods
Between August 2013 and December 2016, suction drain was
used in 67 patients to prevent pocket hematoma during CIED
implantations. All patients provided informed consent for the
procedure. Indication for surgical drain was the use of antith-
rombotic treatment at the time of CIED implantation.is is an open access article under the CC BY-NC-ND license (http://creativecommons.
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In-hospital data during the time of CIED implantation was
extracted from hospital medical records and follow-up data from
device clinic where patients with CIED implantations report for
routine follow-up. Data were tracked from baseline at implanta-
tion until last follow-up at the time of data acquisition.
2.2. Study outcomes
The incidence of pocket hematoma, other bleeding complica-
tions and the incidence of infection post procedure until last follow
up.
3. Deﬁnitions
3.1. Pocket hematoma
Pocket hematomas were diagnosed by cardiologists according
to standardized deﬁnitions. A hematoma was assumed to be
present if there was any palpable swelling of the pacemaker pocket
exceeding the size of the generator. In case of doubt, the presence
of a hematoma was sonographically conﬁrmed. Hematoma related
pain, prolonged hospitalization (i.e., one day more than the
scheduled hospital discharge), or the necessity for reoperation
were recorded.
3.2. Infection
Refers to pocket infection,18 endocarditis19 (either valve or lead)
or blood stream infection.
4. Peri-procedural management of antithrombotic drugs
Patients were either continued on oral anticoagulation or were
bridged with heparin after stopping oral anticoagulants 3–4 days
prior to the procedure. Device implantation was performed when
the INR was within 2–3. We abandoned our practice of bridging
with heparin in patients after the publication of BRIDGE trial
results.20Fig. 1. Close Wound Suction Unit.
Panel A: The short arrow points to the needle with extension tube and long arrow points to
a patient who had undergone device implantation.5. Device implantation and drain ﬁxation
Implantations were performed according to our Institution’s
standard, which remained largely unchanged during the study
period. Brieﬂy, an infraclavicular incision was made and subfascial
pocket was created under local anesthesia. Venous access was
achieved by a separate extra-thoracic subclavian vein puncture.
Electrocautery was used in all patients for making device pocket
and pacemaker generators were routinely placed over pre-pectoral
fascia. Prophylactic antibiotic treatment was given one hour prior
the procedure with a bolus of one gram intravenous cephalosporin
or intravenous clindamycin 600 mg bolus (for patients with allergy
to penicillin). All implantations were performed by experienced
operators.
Post procedure, a sterile, 50 ml capacity closed wound suction
drain of size FG-08 (Mini Vac Set1, Romsons Scientiﬁc & Surgical
Industries Pvt. Ltd., Agra, India) was placed in all patients. The drain
set comprises of two units: needle with extension tube and suction
drain (Fig. 1). The drain was placed in the most dependent area of
the device pocket using the sharp needle assembly. The distal part
of connecting tube was clamped just proximal to needle hub which
was then cut. The suction drain was de-aired and connected to
distal plastic tube and the drain was released. The tube was ﬁxed to
skin by stay sutures. Oral antithrombotics, if withheld were
restarted on the same day of the procedure. Post procedure,
pressure dressing was applied in all patients for 12 h. The drain was
removed when output was less than 10 ml over 24 h.
6. Discharge and follow-up
The patients were discharged from hospital when output from
the drain was less than 10 ml. The pacemaker implantation site was
checked in the device clinic at 3, 10, 30 days after discharge from
the hospital. Further follow-up visits were scheduled every three
months for one year and every six months thereafter. If patients did
not report to device clinic for more than six months, they were
contacted telephonically. If they did not report device clinic for
more than six months and also do not respond to telephonic
review, then they were considered lost to follow up. the suction drain. Panel B: Shows the suction unit in situ in the pacemaker pocket of
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Descriptive statistics were used for patient baseline character-
istics. Continuous variables are reported as mean  standard
deviation and categorical variables as proportion with percentages.
8. Results
Seven hundred and ﬁfty three patients underwent CIED
implantations between August 2013 and December 2016 of which
67 (9%) required continued antithrombotic therapy during the
peri-procedural period. Compelling indications for antithrombotic
use was- recent revascularization for coronary artery disease (CAD)
with coronary angioplasty and stenting/CABG in 22 patients (32%)
followed by atrial ﬁbrillation in 19 patients (28%). The other major
indication was mechanical valve replacement in 11 patients (16%).
The remaining patients included were- stroke in 6 (9%)patients,
CAD without revascularization in 3(4%), recent bioprosthetic valve
replacement in one (1%) and others (5 patients, 7%) Table 1. The
majority were on anticoagulation (40%) or dual anti-platelets
(30%). In 13 (19%) of patients, the procedure was done by
withholding oral antithrombotics and bridging with heparin.
The complete break up of indications and type of antithrombotic
use is given in Table 1.
Thirty two patients (48%) underwent pacemaker implantation,
17 patients (25%) implantable cardioverter deﬁbrillator (ICD)
implantation, 15 (22%) underwent cardiac resynchronization
therapy with ICD (CRT-D) and three (4%) underwent CRT
implantation without ICD.
8.1. In-hospital stay
The mean post-procedure hospital stay was 3  0.9 days
ranging from 2 to 5 days. Volume of drain: The mean overall drain
collected was 16.6 8.2 ml. There was no bleeding beyond 48 h
(second post-procedural day) in 38 (57%) patients and beyond the
fourth day in two patients. At the end of ﬁrst post implantation day,
the average drain collected was 21.5  9.3 ml, ranging from 3 ml to
64 ml. At the end of day 2, it was 16.3  6.9 (range 3 ml to 40 ml)
and day 3, it was 9.9 (2.8 ml), range: 5 ml to 34 ml. One patient
had a pocket hematoma in-hospital, which was managed
conservatively. This patient was on dual antiplatelets for CAD.
He had persistent, severe, unexplained thrombocytopenia which
resulted in bleeding.
8.1.1. Follow up
At a mean follow up of 17.6  8.2 months, there were no further
hematomas. There were no infections. There were ﬁve deaths and
no patients were lost to follow up.Table 1
Indication and type of antithrombotics.
Variables 
Indications S/P PTCA/CABG 
CAD without revasc
S/P valve replaceme
S/P valve replaceme
AF (variable cause) 
CVA 
Othersa
Antithrombotic drugs used Anticoagulant only 
Antiplatelet only 
Antiplatelet + antico
Dual antiplatelets 
S/P: Status Post; PTCA: Percutaneous Transluminal Coronary Angioplasty; CABG: Coronar
Cerebrovascular Accident.
a Other causes include atrial ﬂutter in two patients, left ventricular clot in two patie9. Discussion
The major ﬁnding of the study is that, closed wound drainage
unit during CIED implantations reduces the incidence of pocket
haematoma without increasing the risk of infection in patients
who are at increased risk of bleeding.
9.1. Bleeding complications with continuation of antithrombotic
therapy
The need for antithrombotic therapy is increasing in a large
number of patients undergoing CIED implantations. The procedure
increases the risk of bleeding complications, especially pocket
hematoma.21–23 Previous studies have reported high incidence of
pocket hematoma with both continuation of anticoagulation and
bridging with heparin. With warfarin continuation, the incidence
ranged between 0% to 7.7% 6,9,20,24–28 and with heparin bridging, it
ranged from 5% to as high as 23.7%.9,20,24–28 Dual antiplatelet
therapy is found to be an independent predictor of pocket
hematoma in patients undergoing pacemaker implantations. In
a recent study by Dai et al10 the incidence of pocket hematoma in
this group was found to be 19.3%. In our study, the incidence in this
group of 20 patients was 5%-in the only patient who developed
hematoma. In this patient, the development of hematoma despite
the suction drain is likely due to the underlying thrombocytopenia.
With relation to overall bleeding complications, a meta-
analysis of 13 studies by Bernard et al22 found the incidence rate
to be 2.8 for patients on anticoagulants, 3.9% for patients on single
and 9.4% for dual antiplatelets and 14.6% in whom heparin bridging
was used. With the use of the closed wound suction drain, we did
not observe any bleeding complications except for the hematoma
in one patient (1.4%).
9.2. Risk of infection
Infection is a devastating complication associated with CIED
implantations. Several factors contribute to infections11,12,29
among which hematoma is considered an important factor.
Hematoma is the only independent predictor and is associated
with a > 7- fold increased risk of infection.1 In about 1–2% of
implant cases, re-explorations are needed to evacuate hematoma
or arrest bleeders which in turn increases the risk of infection.2 It is
also known that empirical use of antibiotics do not prevent
infection in the presence of hematoma due to poor penetration
into extravascular space of pocket.1 Thus modes to reduce blood
collection is of paramount importance.
The present study emphasizes that surgical drain reduces
hematoma incidence and has no associated long term increased
risk of infection. The mean hospital stay was more than the usualFrequency (%)
22 (32%)
ularization 3 (4%)
nt with mechanical valve 11(16%)
nt with bioprosthetic valve 1 (1%)
19 (28%)
6 (9%)
5 (7%)
27 (40%)
3 (4%)
agulant 17 (25%)
20 (30%)
y Artery Bypass Grafting; CAD: Coronary Artery Disease; AF: Atrial Fibrillation; CVA:
nts, and arterial thrombosis in one patient.
S392 S.S. Mukherjee et al. / Indian Heart Journal 70 (2018) S389–S393stay duration for patients without suction drains in our hospital.
This implies increase in hospitalization costs but, this increase is
offset by reduction in hematoma and subsequent infection which
may signiﬁcantly lengthen the hospital stay. With device implant
rates and the indications of antithrombotics on the rise, this
technique has the potential to beneﬁt signiﬁcant proportion of
people undergoing CIEDs.
9.3. Study limitation
This is a retrospective collection of data in a small cohort of
patients, which may be associated with selection bias. We
considered device infection only when patient required hospitali-
zation, which might overlook any outpatient treatment if received.
But this was necessary as an objective and clinically meaningful
end point. Decisions to re-intervene were not well deﬁned. We had
very few patients on novel anticoagulants and none on prasugrel/
ticagrelor which are common in current practice. The procedures
were done by experienced operators of a high volume centre and
so results cannot be generalized.
10. Conclusion
Use of a surgical drain reduces the occurrence of pocket
hematoma and subsequent infection in patients with high risk of
bleeding undergoing cardiac device implantations.
Author contribution
Sanjeev S Mukherjee was involved in the design of the study,
data analysis and interpretation, drafting article, critical revision of
article and approval of the article.
Daljeet Saggu was involved in critical revision of article and
approval of article.
Sridevi Chennapragada was involved in the concept of the
study, critical revision and approval of the article.
Sachin Yalagudri was involved in critical revision and approval
of the article.
Sandeep G. Nair was involved in critical revision and approval of
article.
Calambur Narasimhan was involved in the concept of the study,
drafting the article, critical revision and approval of article.
These high risk patients may be able to continue antiplatelet/
anticoagulant therapy during implant of cardiac devices.
Financial assistance
None.
Conﬂict of interest
None to declare.
Acknowledgements
The authors acknowledge Ms. Nalla Swapna and Mr. David
Sampathkumar, Physician Assistants for data retrieval and patient
interviews and Mr. C. Ranjith for his assistance in data entry.
References
1. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and
arrhythmia’s project. Pacing Clin Electrophysiol. 2011;34(8):1013–102710.1111/
j.1540-8159.2011.03150.x.
2. Ector H, P.V. Current use of pacemakers, implantable cardioverter
deﬁbrillators, and resynchronization devices: data from the registry of the
European Heart Rhythm Association. Eur Hear J Suppl. 2007;9:144–149.3. Shenthar J, Bohra S, Jetley V, et al. A survey of cardiac implantable electronic
device implantation in India: by Indian Society of Electrocardiology and Indian
Heart Rhythm Society. Indian Heart J. 2016;68(1):68–7110.1016/j.
ihj.2015.06.037.
4. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter–
deﬁbrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–
23710.1056/NEJMoa043399.
5. Greenspon Arnold J, Hart Robert G, Dawson David, et al. Predictors of stroke in
patients paced for sick sinus syndrome. J Am Coll Cardiol. 2004;43(9):1617–
162210.1016/j.jacc.2003.09.067.
6. Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD. Implantation of
cardiac rhythm devices without interruption of oral anticoagulation compared
with perioperative bridging with low-molecular weight heparin. Am Heart J.
2009;158(2):252–25610.1016/j.ahj.2009.06.005.
7. Sridhar ARM, Yarlagadda V, Kanmanthareddy A, et al. Incidence, predictors
and outcomes of hematoma after ICD implantation: an analysis of a
nationwide database of 85,276 patients. Indian Pacing Electrophysiol J. 2016;16
(5):159–16410.1016/j.ipej.2016.10.005.
8. Yalcin M, Isilak Z, Bicakci B, Uz O. Risk factors of pocket hematoma in patients
with electrophysiological device implantation. Eur Rev Med Pharmacol Sci.
2015;19(17)3135–3136 http://www.ncbi.nlm.nih.gov/pubmed/26400510.
Accessed February 6, 2017.
9. Proietti R, Porto I, Levi M, et al. Risk of pocket hematoma in patients on chronic
anticoagulation with warfarin undergoing electrophysiological device
implantation: a comparison of different peri-operative management
strategies. Eur Rev Med Pharmacol Sci. 2015;19(8)1461–1479 http://www.ncbi.
nlm.nih.gov/pubmed/25967723. Accessed February 6, 2017.
10. Dai Y, Chen K-P, Hua W, Zhang J-T, Zhang S. Dual antiplatelet therapy increases
pocket hematoma complications in Chinese patients with pacemaker
implantation. J Geriatr Cardiol. 2015;12(4):383–38710.11909/j.issn.1671-
5411.2015.04.010.
11. Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted
pacemakers and cardioverter-deﬁbrillators: results of a large prospective
study. Circulation. 2007;116(12):1349–135510.1161/
CIRCULATIONAHA.106.678664.
12. Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay
associated with cardiac device infections: leiden device registry. Heart.
2009;95(9):715–72010.1136/hrt.2008.151985.
13. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable
electronic device infection: a systematic review and meta-analysis. Europace.
2015;17(5):767–77710.1093/europace/euv053.
14. Healey Jeff S, Eikelboom John, Douketis James, et al. Periprocedural bleeding
and thromboembolic events with dabigatran compared with warfarin clinical
perspective. Circulation. 2012;126(3).
15. Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing
rivaroxaban compared with warfarin in patients with nonvalvular atrial
ﬁbrillation. J Am Coll Cardiol. 2013;61(6):651–65810.1016/j.jacc.2012.09.057.
16. Marquie C, De Geeter G, Klug D, et al. Post-operative use of heparin increases
morbidity of pacemaker implantation. Europace. 2006;8(4):283–28710.1093/
europace/eul011.
17. Robinson M, Healey JS, Eikelboom J, et al. Postoperative low-Molecular-Weight
heparin bridging is associated with an increase in wound hematoma following
surgery for pacemakers and implantable deﬁbrillators. Pacing Clin
Electrophysiol. 2009;32(3):378–38210.1111/j.1540-8159.2008.02247.x.
18. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance deﬁnition of health
care–associated infection and criteria for speciﬁc types of infections in the
acute care setting. Am J Infect Control. 2008;36(5):309–33210.1016/j.
ajic.2008.03.002.
19. Li JS, Sexton DJ, Mick N, et al. Proposed modiﬁcations to the duke criteria for
the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633–
63810.1086/313753.
20. Wight JM, Columb MO. Perioperative bridging anticoagulation for atrial
ﬁbrillation—the ﬁrst randomised controlled trial. Perioper Med. 2016;5
(1):1410.1186/s13741-016-0040-5.
21. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of
antithrombotic therapy. Chest. 2012;141(2):e326S–e350S10.1378/chest.11-
2298.
22. Bernard ML, Shotwell M, Nietert PJ, Gold MR. Meta-analysis of bleeding
complications associated with cardiac rhythm device implantation. Circ
Arrhythm Electrophysiol. 2012;5(3):468–47410.1161/CIRCEP.111.969105.
23. Thal S, Moukabary T, Boyella R, et al. The relationship between warfarin,
aspirin, and clopidogre. Pacing Clin Electrophysiol. 2010;388:10.1111/j.1540-
8159.2009.02674.x.
24. Amara W, Ben Youssef I, Kamel J, Ghrissi I, Faron M, Khouadja ASJ. Hemorrhagic
risk of different perioperative anticoagulation protocols in patients implanted
with a cardiac pacemaker or deﬁbrillator: retrospective analysis in patients
implanted in a community hospital. Ann Cardiol Angeiol. 2009;58(5):265–271.
25. Ahmed I, Gertner E, Nelson WB, et al. Continuing warfarin therapy is superior
to interrupting warfarin with or without bridging anticoagulation therapy in
patients undergoing pacemaker and deﬁbrillator implantation. Hear Rhythm.
2010;7(6):745–74910.1016/j.hrthm.2010.02.018.
26. Cheng M, Hua W, Chen K, et al. Perioperative anticoagulation for patients with
mechanic heart valve(s) undertaking pacemaker implantation. Europace.
2009;11(9):1183–118710.1093/europace/eup212.
27. Tolosana JM, Berne Mont PL, et al. Preparation for pacemaker or implantable
cardiac deﬁbrillator implants in patients with high risk of thrombo-embolic
S.S. Mukherjee et al. / Indian Heart Journal 70 (2018) S389–S393 S393events: oral anticoagulation or bridging with intravenous heparin? A
prospective randomized trial. Eur Heart J. 2009;30(15):1880–188410.1093/
eurheartj/ehp194.
28. Milic D, Perisic Z, Zivic S, et al. Prevention of pocket related complications with
ﬁbrin sealant in patients undergoing pacemaker implantation who arereceiving anticoagulant treatment. Europace. 2005;7(4):374–37910.1016/j.
eupc.2005.03.007.
29. Sohail Muhammad R, Uslan Daniel Z, Khan Akbar H, et al. Baddour risk factor
analysis of permanent pacemaker infection. Clin Infect Dis. 2007;45(2):166–
173.
